Regeneron Pharmaceuticals (REGN) Total Non-Current Liabilities (2009 - 2026)

Regeneron Pharmaceuticals has reported Total Non-Current Liabilities for 18 years, with the latest figure at $7.7 billion in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 17.62% year-over-year to $7.7 billion in Q2 2026; TTM through Jun 2026 was $7.7 billion, a 17.62% increase from a year earlier, with the FY2025 full-year figure at $7.3 billion, up 6.56% from the prior year.
• Total Non-Current Liabilities was $7.7 billion for Q2 2026 at Regeneron Pharmaceuticals, up from $7.3 billion in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $7.7 billion in Q2 2026, with the low at $5.6 billion in Q3 2022.
• Average Total Non-Current Liabilities over 5 years is $6.5 billion, with a median of $6.4 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2026: Total Non-Current Liabilities dropped 1.92% in 2022, then grew 17.62% in 2026.
• Over 5 years, Total Non-Current Liabilities stood at $5.9 billion in 2022, then rose by 5.76% to $6.3 billion in 2023, then grew by 9.3% to $6.8 billion in 2024, then advanced by 6.56% to $7.3 billion in 2025, then increased by 6.24% to $7.7 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $7.7 billion (Q2 2026), $7.3 billion (Q1 2026), and $7.3 billion (Q4 2025), per Business Quant data.